---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034159"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:34:48.519983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed

## Summary
- Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.
- Cash, cash equivalents and marketable securities $83.0M at year-end 2023; expected runway into 2026.
- Phase 2a RIVER trial for RCC topline data expected H2 2024; enrollment continuing across multiple sites.
- Phase 2b CORAL trial for chronic cough in IPF topline expected H1 2025; SSRE expected H2 2024.
- Human Abuse Potential study over 50% enrolled; topline data expected H2 2024.

## SEC filing metadata
- accession: 0000950170-24-034159
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/0000950170-24-034159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/trvi-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034159
- JSON: https://secwatch.observer/filing/0000950170-24-034159.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034159.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: net income Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.. Guidance reaffirmed.
  - Period: quarter and year ended December 31, 2023
  - Net income: Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.
  - Guidance: reaffirmed
  - Result: reported results
  source text: Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/0000950170-24-034159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.